List view / Grid view
In an exclusive interview, Dr Neville Sanjana, Associate Professor of biology at NYU and a core faculty member at the New York Genome Center, discusses the breakthrough study on STING-seq.
25 July 2023 | By Eurofins Discovery
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
Researchers from Tokyo Tech's World Research Hub Initiative conducted a study to investigate the regulation of gene expression in the apicoplast of the malaria parasite Plasmodium falciparum.
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
Central nervous system (CNS) research is making breakthroughs with innovative therapies and next-generation technologies. Researchers are now able to use human tissue to identify relevant novel drug targets and biomarkers for a broad range of CNS diseases including schizophrenia, Alzheimer’s disease and Parkinson’s disease. As our understanding of the brain…
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
Tomographic phase microscopy in flow cytometry showcases its ability to accurately measure intracellular lipid droplets.
This ebook outlines the basics of fluorescence polarization and discusses the advantages and limitations of FP-based biochemical assays.
Dr Marina Junqueira explores the main research interest of a lab focusing on opioids, cannabinoids, terpenoids and 5HT receptor agonists with the aim to understand the molecular-level signaling of drugs and how polymorphisms can affect this process.
27 June 2023 | By Eurofins Discovery
US-FDA recommend integration of both preclinical (S7B) and clinical (E14) data to improve risk assessment, reduce reliance on TQT clinical studies, streamlined drug-development, simplified decision-making processes, effective risk-communication.
In this eBook, explore how cutting-edge imaging modalities can elevate your biomedical research.
27 June 2023 | By
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.
